How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?

Following the NADINA trial data, what is your preferred treatment approach for patients with resectable stage III melanoma without BRAF mutation?

• Neoadjuvant nivolumab/ipilimumab
• Neoadjuvant pembrolizumab
• Neoadjuvant nivolumab
• Neoadjuvant nivolumab/relatlimab
• Upfront resection followed by adjuvant nivolumab
• Upfront resection followed by adjuvant pembrolizumab
• Other